Laboratory Research
Chitsazzadeh V, Coarfa C, Drummond JA, Nguyen T, Joseph A, Chilukuri S, Charpiot E, Adelmann CH, Ching G, Nguyen TN, Nicholas C, Thomas VD, Migden M, MacFarlane D, Thompson E, Shen J, Takata Y, McNiece K, Polansky MA, Abbas HA, Rajapakshe K, Gower A, Spira A, Covington KR, Xiao W, Gunaratne P, Pickering C, Frederick M, Myers JN, Shen L, Yao H, Su X, Rapini RP, Wheeler DA, Hawk ET, Flores ER, Tsai KY. Cross-species identification of genomic drivers of squamous cell carcinoma development across preneoplastic intermediates. Nat Commun. 2016 Aug 30;7:12601. doi: 10.1038/ncomms12601, PMID: 27574101.
Napoli M, Venkatanarayan A, Raulji P, Meyers BA, Norton W, Mangala LS, Sood AK, Rodriguez-Aguayo C, Lopez-Berestein G, Vin H, Duvic M, Tetzlaff MB, Curry JL, Rook AH, Abbas HA, Coarfa C, Gunaratne PH, Tsai KY, Flores ER. ΔNp63/DGCR8-Dependent MicroRNAs Mediate Therapeutic Efficacy of HDAC Inhibitors in Cancer. Cancer Cell. 2016 Jun 13;29(6):874-88. doi: 10.1016/j.ccell.2016.04.016, PMID: 27300436.
Adelmann CH, Truong KA, Liang RJ, Bansal V, Gandee L, Saporito RC, Lee W, Du L, Nicholas C, Napoli M, Mino B, South AP, Proby CM, Leigh IM, Coarfa C, Flores ER, Tsai KY. MEK Is a Therapeutic and Chemopreventative Target in Squamous Cell Carcinoma. J Invest Dermatol. 2016 Sep;136(9):1920-4. doi: 10.1016/j.jid.2016.05.110. PMID: 27293029.
Adelmann CH, Ching G, Du L, Saporito RC, Bansal V, Pence LJ, Liang R, Lee W, Tsai KY. Comparative profiles of BRAF inhibitors: the paradox index as a predictor of clinical toxicity. Oncotarget. 2016 May 24;7(21):30453-60. doi: 10.18632/oncotarget.8351. PMID: 27028853.
Feldmeyer L, Ching G, Vin H, Ma W, Bansal V, Chitsazzadeh V, Jahan-Tigh R, Chu EY, Fuller P, Maiti S, Davis RE, Cooper LJ, Tsai KY. Differential T-cell subset representation in cutaneous squamous
cell carcinoma arising in immunosuppressed versus immunocompetent individuals. Exp Dermatol 25(3):245-7, 3/2016. e-Pub 11/2015. PMID: 26475987.
Maresso KC, Tsai KY, Brown PH, Szabo E, Lippman S, Hawk ET. Molecular cancer prevention: Current status and future directions. CA Cancer J Clin 65(5):345-83, Sep-Oct, 9/2015. e-Pub 8/2015. PMID:
26284997.
Amaravadi RK, Hamilton KE, Ma X, Piao S, Portillo AD, Nathanson KL, Carlino MS, Long GV, Puzanov I, Xu X, Morrissette JJ, Tsai KY, Flaherty KT, Sosman JA, Goodman GR, McArthur GA, Rustgi AK, Metz DC,
Schuchter LM, Chapman PB, Sepulveda AR. Multiple gastrointestinal polyps in patients treated with BRAF inhibitors. Clin Cancer Res 21(23):5215-21, 12/2015. e-Pub 7/2015. PMCID: PMC4668213.
Cancer Genome Atlas Network. Genomic Classification of Cutaneous Melanoma. Cell 161(7):1681-96, 6/2015. PMID: 26091043.
Warthaka M, Adelmann CH, Kaoud TS, Edupuganti R, Yan C, Johnson WH, Ferguson S, Tavares CD, Pence LJ, Anslyn EV, Ren P, Tsai KY, Dalby KN. Quantification of a Pharmacodynamic ERK End Point in
Melanoma Cell Lysates: Toward Personalized Precision Medicine. ACS Med Chem Lett 6(1):47-52, 1/2015. e-Pub 10/2014. PMCID: PMC4291693.
Fowler NH, Davis RE, Rawal S, Nastoupil L, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale MA, Fayad LE, Westin JR, Shah J, Orlowski RZ, Wang M, Turturro F, Oki Y, Claret LC, Feng L,
Baladandayuthapani V, Muzzafar T, Tsai KY, Samaniego F, Neelapu SS. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol
15(12):1311-8, 11/2014. e-Pub 10/2014. PMID: 25439689.
Venkatanarayan A, Raulji P, Norton W, Chakravarti D, Coarfa C, Su X, Sandur SK, Ramirez MS, Lee J, Kingsley CV, Sananikone EF, Rajapakshe K, Naff K, Parker-Thornburg J, Bankson JA, Tsai KY, Gunaratne
PH, Flores ER. IAPP-driven metabolic reprogramming induces regression of p53-deficient tumours in vivo. Nature 517(7536):626-30, 1/2015. e-Pub 11/2014. PMCID: PMC4312210.
Pickering CR, Zhou JH, Lee JJ, Drummond JA, Peng SA, Saade RE, Tsai KY, Curry JL, Tetzlaff MT, Lai SY, Yu J, Muzny DM, Doddapaneni H, Shinbrot E, Covington KR, Zhang J, Seth S, Caulin C, Clayman GL,
El-Naggar AK, Gibbs RA, Weber RS, Myers JN, Wheeler DA, Frederick MJ. Mutational landscape of aggressive cutaneous squamous cell carcinoma. Clin Cancer Res 20(24):6582-92, 12/2014. e-Pub 10/2014.
PMID: 25303977.
Ma Q, Li D, Carreño R, Patenia R, Tsai KY, Xydes-Smith M, Alousi AM, Champlin RE, Sale GE, Afshar-Kharghan V. Bone Marrow Transplant. 2014 Apr 28. doi: 10.1038/bmt.2014.75. PMID: 24777193
Chakravarti D, Su X, Cho MS, Bui NH, Coarfa C, Venkatanarayan A, Benham AL, Flores González RE, Alana J, Xiao W, Leung ML, Vin H, Chan IL, Aquino A, Müller N, Wang H, Cooney AJ, Parker-Thornburg J,
Tsai KY, Gunaratne PH, Flores ER. Induced multipotency in adult keratinocytes through down-regulation of ΔNp63 or DGCR8. Proc Natl Acad Sci U S A. 2014 Feb 4;111(5):E572-81. doi:
10.1073/pnas.1319743111. PMID: 24449888
Vin H, Ojeda SS, Ching G, Leung ML, Chitsazzadeh V, Dwyer DW, Adelmann CH, Restrepo M, Richards KN, Stewart LR, Du L, Ferguson SB, Chakravarti D, Ehrenreiter K, Baccarini M, Ruggieri R, Curry JL, Kim
KB, Ciurea AM, Duvic M, Prieto VG, Ullrich SE, Dalby KN, Flores ER, Tsai KY*. BRAF inhibitors suppress apoptosis through off-target inhibition of JNK signaling. Elife 2(0). doi:pii: e00969.
10.7554/eLife.00969. 11/2013. PMID: 24192036
Vin H, Ching G, Ojeda S, Adelmann CH, Chitsazzadeh V, Dwyer D, Ma H, Ehrenreiter K, Baccarini M, Ruggieri R, Curry J, Ciurea AM, Duvic M, Busaidy NL, Tannir NM, Tsai KY*. Sorafenib suppresses
JNK-dependent apoptosis through inhibition of ZAK. Mol Cancer Ther. Oct 29, 2013. [Epub] PMID: 24170769
Hwang BH, Tsai KY, Mitragotri S. Optimized lysis buffer reagents for solubilization and preservation of proteins from cells and tissues. Drug Deliv and Transl Res. 3: 428-436, 1/2013.
Paliwal S, Hwang BH, Tsai KY*, Mitragotri S*. Diagnostic opportunities based on skin biomarkers. Eur J Pharm Sci. 50(5): 546-56. 12/2012. PMID: 23159445
Hwang BH, Doshi N, Tsai KY*, Mitragotri S*. A reagent to facilitate protein recovery from cells and tissues. Drug Deliv and Transl Res. 2:297-304, 10/2012.
Su X, Gi YJ, Chakravarti D, Cham IL, Zhang A, Xia X, Tsai KY, Flores, ER. TAp63 is a master transcriptional regulator of lipid and gluclose metabolism. Cell Metab. 16(4): 511-26, 11/2012. PMID:
23040072
Rangwala S, Tsai KY. Roles of the Immune System in Cancer. Br J Dermatol. 165(5): 953-65, 11/2011. PMID: 21729024
Yang G, Thieu K, Tsai KY, Piris A, Udayakumar D, Njauw C-NJ, Ramoni M, Tsao H. Dynamic Gene Expression Analysis Links Melanocyte Growth Arrest with Nevogenesis. Cancer Res 69(23):9029-37, 12/2009.
e-Pub 11/2009. PMID: 19903842.
Su X, Paris M, Gi YJ, Tsai KY, Cho MS, Lin YL, Biernaskie JA, Sinha S, Prives C, Pevny LH, Miller FD, Flores ER. TAp63 prevents premature aging by promoting adult stem cell maintenance. Cell Stem
Cell 5(1):64-75, 7/2009. PMID: 19570515.
Niendorf KB, Goggins W, Yang G, Tsai KY, Shennan M, Bell DW, Sober AJ, Hogg D, Tsao H. MELPREDICT: a logistic regression model to estimate CDKN2A carrier probability. J Med Genet 43(6):501-6, 6/2006.
PMID: 16169933.
Flores ER, Tsai KY, Crowley D, Sengupta S, Yang A, McKeon F, Jacks T. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 416(6880):560-4, 4/2002. PMID:
11932750.
Tsai KY, MacPherson D, Rubinson DA, Crowley D, Jacks T. ARF is not required for apoptosis in Rb mutant mouse embryos. Curr Biol 12(2):159-63, 1/2002. PMID: 11818069.
Geng Y, Yu Q, Whoriskey W, Dick F, Tsai KY, Ford HL, Biswas DK, Pardee AB, Amati B, Jacks T, Richardson A, Dyson N, Sicinski P. Expression of cyclins E1 and E2 during mouse development and in
neoplasia. Proc Natl Acad Sci U S A 98(23):13138-43, 11/2001. PMID: 11687642.
Irwin M, Marin MC, Phillips AC, Seelan RS, Smith DI, Liu W, Flores ER, Tsai KY, Jacks T, Vousden KH, Kaelin WG. Role for the p53 homologue p73 in E2F-1-induced apoptosis. Nature 407(6804):645-8,
10/2000. PMID: 11034215.
Alenghat FJ, Fabry B, Tsai KY, Goldmann WH, Ingber DE. Analysis of cell mechanics in single vinculin deficient cells using a magnetic tweezer. Biochem Biophys Res Commun 277(1):93-9, 10/2000. PMID:
11027646.
Boyd SD, Tsai KY, Jacks T. An intact HDM2 RING-finger domain is required for nuclear exclusion of p53. Nat Cell Biol 2(9):563-8, 9/2000. PMID: 10980695.
Tsai KY, Hu Y, Macleod KF, Crowley D, Yamasaki L, Jacks T. Mutation of E2f-1 suppresses apoptosis and inappropriate S phase entry and extends survival of Rb-deficient mouse embryos. Mol Cell
2(3):293-304, 9/1998. PMID: 9774968.
Lee KM, Tsai KY, Wang N, Ingber DE. Extracellular matrix and pulmonary hypertension: control of vascular smooth muscle cell contractility. Am J Physiol 274(1 Pt 2):H76-82, 1/1998. PMID:
9458854.
Carnevale NT, Tsai KY, Claiborne BJ, Brown TH. Comparative electrotonic analysis of three classes of rat hippocampal neurons. J Neurophysiol 78(2):703-20, 8/1997. PMID: 9307106.
Hoffman RE, Buchsbaum MS, Jensen RV, Guich SM, Tsai KY, Neuchterlein KH. Dimensional complexity of EEG waveforms in neuroleptic-free schizophrenics and normal controls. J Neuropsych Clin Neurosci
8:436-441, 1996. PMID: 9116481.
Tsai KY, Carnevale NT, Brown TH. Hebbian learning is jointly controlled by electrotonic and input structure. Network 5(1):1-19, 2/1994.
Tsai KY, Carnevale NT, Claiborne BJ, Brown TH. Efficient mapping from neuroanatomical to electrotonic space. Network 5(1):21-46, 2/1994.
Dermatology / Dermatopathology Papers
Curry JL, Tetzlaff MT, Nicholson K, Duvic M, Kim KB, Tsai KY, Hwu WJ, Hong DS, Prieto VG, Torres-Cabala CA. Am J Dermatopathol. 2014 Jul;36(7):557-61. PMID: 24950418
Pattanaprichakul P, Tetzlaff MT, Lapolla WJ, Torres-Cabala CA, Duvic M, Prieto VG, Tsai KY, Curry JL. J Cutan Pathol. 2014 Mar;41(3):326-8. doi: 10.1111/cup.12273. PMID: 24372055
Tsai KY, Nowroozi S, Kim KB. Drug safety evaluation of vemurafenib in the treatment of melanoma. Expert Opin Drug Saf 12(5): 767-75, 9/2013. PMID: 23800008
Curry JL, Torres-Cabala CA, Kim KB, Tetzlaff MT, Duvic M, Tsai KY, Hong DS, Prieto VG. Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions. Int J
Dermatol. Jul 24, 2013 [Epub]. PMID: 23879247
Matthias N, Lockworth CR, Zhang F, Lee MH, Yeung SC, Tsai KY, Hamir AN. Multiple cystic sweat gland tumors in transgenic mice. Comp Med. 2012;62(1):27-30. PMID: 22330648
Tsai KY. Assessing the treatment of nonmelanoma skin cancers. Arch Dermatol. 147(5):605-6, 5/2011. PMID: 21576581.
Silapunt S, Jordon RE, Piao Y, Tsai KY. Kaposi sarcoma presenting as a cutaneous horn. J Am Acad Dermatol 64(2):447-8, 2/2011. PMID: 21238839.
Bergman H, Tsai KY, Seo SJ, Kvedar JC, Watson AJ. Remote assessment of acne: the use of acne grading tools to evaluate digital skin images. Telemed J E Health 15(5):426-30, 6/2009. PMID:
19548822.
Tucker JD, Shah S, Jarell AD, Tsai KY, Zembowicz A, Kroshinsky D. Lues Maligna in Early HIV Infection Case Report and Review of the Literature. Sex Transm Dis. e-Pub 5/2009. PMID: 19455078.
Davis TL, Mandal RV, Bevona C, Tsai KY, Moschella SL, Staszewski R, Zembowicz A. Collagenous vasculopathy: a report of three cases. J Cutan Pathol 35(10):967-70, 6/2008. PMID: 18537865.
Tsai KY, Brenn T, Werchniak AE. Nodular presentation of secondary syphilis. J Am Acad Dermatol 57(2 Suppl):S57-8, 8/2007. PMID: 17637381.
Tsai KY. Systemic adjuvant therapy for patients with high-risk melanoma. Arch Dermatol 143(6):779-82, 6/2007. PMID: 17576946.
Tsai KY, Tsao H. Primer on the human genome. J Am Acad Dermatol 56(5):719-35, 5/2007. PMID: 17437886.
Tsai KY. A potential pathogenic role for aberrant DNA rearrangements in bridging dyscrasias of undetermined significance and lymphoma? Arch Dermatol 141(11):1468-9, 11/2005. PMID: 16301403.
Tsai KY. Evidence-based medicine: do we use guidelines or mindlines? Commentary on: Evidence based guidelines or collectively constructed "mindlines?" ethnographic study of knowledge management in
primary care. Gabbay J, le May G BMJ. 2004;329:1013. Arch Dermatol 141(6):773-4, 6/2005. PMID: 15967926.
Tsai KY, Tsao H. The genetics of skin cancer. Am J Med Genet C Semin Med Genet 131C(1):82-92, 11/2004. PMID: 15468170.
Copyright Kenneth Y. Tsai, 2011, Created with 1&1 WebsiteBuilder